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histone-mutant diffuse midline gliomas, these cytoarchitec-
tural characteristics are taken into account when assigning 
a malignancy grade to the tumour according to the WHO 
classification scheme [28]. This is still the mainstay of the 
diagnostic approach and is suitable and adequate for the vast 
majority of tumours, including brain tumours. While a small 
proportion of brain tumours in adults is caused by germ line 
mutations and is associated with a number of syndromes, the 
majority of adult gliomas develop sporadically. Recent com-
bined efforts by large research consortia have, however, led 
to the discovery of a number of key mutations, chromosome 
copy number variations and epigenetic alterations in a range 
of intrinsic brain tumours [27], challenging the clinical rel-
evance of the traditional diagnostic approach. The first most 
detailed molecular subclassification of brain tumours has 
been achieved with medulloblastomas, a malignant, predom-
inantly paediatric, brain tumour arising in the cerebellum, 
whereby the gene expression profile reflects the activation of 
distinct signalling pathways and correlates much better with 
clinical outcome and therapy response than the conventional 
subclassification approaches based on histological features 
[54]. In adults, the most common intrinsic brain tumours are 
gliomas, such as glioblastomas, astrocytomas, oligodendro-
gliomas and ependymomas, arising throughout the neuraxis 
and displaying variable biological behaviour. The discov-
ery of mutations in specific genes has revolutionised our 
understanding of the pathogenesis of many type of glioma 
and has subsequently led to a biomarker-driven classifica-
tion which in current practice not only supplements, but 
increasingly overrides the histological diagnosis. Another 
important development is the recognition of clinically rel-
evant, molecularly defined tumour classes. Mounting evi-
dence indicates that for certain nosological entities, for 
example, IDH-mutant astrocytomas [40] or ependymomas 
[31], the molecular profile much better reflects the biological 
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Introduction
The traditional approach to diagnose brain tumours is the 
examination of a histological specimen. Conventionally, 
pathologists make the histological diagnosis by assess-
ing morphological features of cellular atypia, variation of 
nuclear size (anisonucleosis), shape (pleomorphism), mitotic 
activity, cell density, characteristic architectural patterns, 
vascular properties, and cell necrosis. With the exception of 
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behaviour, superseding the relevance of conventional his-
tological grading, which is based on histological features.
The focus of this review article is limited to primary, 
intrinsic brain tumours occurring in adults. Each molecularly 
defined diagnostic group, i.e. IDH-mutant astrocytomas or 
oligodendrogliomas, histone-mutant gliomas, BRAF-mutant 
gliomas and ependymomas will be discussed separately with 
an emphasis on the specific molecular alterations in each 
group and their clinical relevance.
IDH‑mutant gliomas: astrocytomas, glioblastomas 
and oligodendrogliomas
Genetics and pathology
The discovery of mutations in the isocitrate dehydrogenase 
genes 1 and 2 (IDH1, IDH2) in 2008 was a major break-
through towards molecular biomarker-driven diagnosis of 
adult gliomas [34]. Mutations on codon 132 or 172 of the 
IDH1 and IDH2 genes, respectively, results in “neo-enzy-
matic activity” with the production of the novel oncome-
tabolite 2-hydroxyglutarate [11] causing widespread meth-
ylation of the tumour cell DNA [55] and altered regulation 
of histone methylation [9]. IDH-mutant gliomas mainly arise 
in young adults in their second to fourth decade of life and 
are rare in people over 55 [7]. IDH mutations occur in two 
classes of gliomas, astrocytomas and oligodendrogliomas. 
IDH-mutant astrocytomas over time progress to IDH-mutant 
anaplastic astrocytomas and IDH-mutant glioblastomas, pre-
viously also known as secondary glioblastomas. However, 
the IDH-mutant anaplastic astrocytoma and IDH-mutant 
glioblastoma can also develop de novo with no previous 
clinical and radiological evidence of a lower grade glioma. 
The majority (90%) of both astrocytomas and oligoden-
drogliomas carry a specific point mutation (R132H) in the 
IDH1 gene [19], which can be detected immunohistochemi-
cally with a mutation-specific antibody [5]. The detection 
of the other mutations (Fig. 1) requires sequencing of the 
IDH1 and IDH2 genes [20, 36]. The presence of an IDH1 
or IDH2 mutation is also required for the diagnosis of oligo-
dendroglioma and anaplastic oligodendroglioma. The pre-
viously known entity of oligoastrocytoma was defined on 
histological grounds only and is now extinct [44], as there is 
robust evidence that the IDH mutations segregate either with 
the chromosomal codeletion of 1p/19q in oligodendroglio-
mas, or with a loss of function mutation in the ATRX gene 
(alpha thalassaemia/mental retardation syndrome X-linked) 
IDH1 G395A R132H 88% IDH1 C394T R132C 4%
IDH1 C394A R132S 1%
IDH1 C394G R132G 1%
IDH1 G395T R132L <1%
IDH2 G515A R172K 3%
IDH2 G515T R172M 1%
IDH2 A514T R172W 1%
IDH2 G516T R172S <1%
IDH2 A514G R172G <1%
Fig. 1  Frequency of IDH1 and IDH2 mutations in a cohort of 747 
oligodendroglial and astrocytic tumours (extracted from the data in 
[19]) and two added rare IDH2 mutations. The left part of the graph 
shows a typical histological image of immunostaining in an IDH1 
R132H mutant astrocytoma with an antibody detecting this specific 
mutation. Approximately 90% of all IDH-mutant tumours and 95% of 
IDH1 mutations are detected with this antibody. The remaining IDH1 
mutations and all IDH2 mutations are most commonly detected by 
sequencing the hotspot on codon 132 (IDH1) and 172 (IDH2) (right 
part of the figure). The frequency of IDH-mutant gliomas rapidly 
decreases with the age of the patient. The probability of an alternative 
IDH mutation is < 6% in a 50-year-old patient and decreases to < 1% 
in patients aged > 54 years [7]
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in astrocytomas [41] (Fig. 2). Combined 1p/19q loss (also 
known as 1p/19q codeletion) can be tested with a number of 
molecular methods, such as fluorescent in situ hybridisation 
(FISH), qPCR and various array technologies. Mutations 
in the ATRX gene are routinely tested in most laboratories 
by immunostaining for the ATRX protein, which detects 
loss of expression resulting from the majority of ATRX 
gene mutations [23, 25]. However, a small proportion of 
mutations in the ATRX gene does not result in the loss of 
protein expression, and thus are not detectable by immu-
nohistochemistry. Sequencing of the ATRX gene would be 
desirable, but is currently not practical in routine diagnos-
tics in most laboratories, due to the large size of the ATRX 
gene and the wide range of mutation sites. Diagnostically 
Fig. 2  Simplified scheme of known genetic alterations in the most 
common glial and glioneuronal tumours. The inner circle shows the 
presumed driver mutation, such as IDH (green), histone H3.3 K27M, 
G34R, FGFR–TACC fusion (brown), or BRAF alterations (dark 
blue), MYB/MYBL1, PIK3CA and FGFR1 (lighter blue shades). The 
middle circle shows known additional mutations that are associated 
with the respective tumour entities. For example, in the group of 
IDH-mutant tumours, the 1p/19q codeletion defines the oligodendro-
glioma, whilst the ATRX mutation defines the IDH-mutant astrocy-
toma. The IDH-wildtype glioblastoma (light brown) currently does 
not have a defined driver mutation, but it contains a combination of 
signature alterations such as EGFR or PDRGRA amplifications, TERT 
promoter mutation and others. The outer circle shows the histologi-
cal diagnosis with the abbreviations corresponding to the follow-
ing histological entities: A astrocytoma, AA anaplastic astrocytoma, 
GBM glioblastoma, O oligodendroglioma, AO anaplastic oligoden-
droglioma, PXA pleomorphic xanthoastrocytoma, APXA anaplastic 
pleomorphic xanthoastrocytoma, GG ganglioglioma, AGG anaplastic 
ganglioglioma, PA pilocytic astrocytoma, DLGNT diffuse leptome-
ningeal glioneuronal tumour, RGNT rosette forming glioneuronal 
tumour. The grey shades for each histological diagnosis indicate the 
prognosis: light grey corresponds to good prognosis and darkest grey 
corresponds to poorest prognosis. Note that tumours with identical 
histological diagnoses, depending on their underlying genetic altera-
tion, can show different biological behaviour and thus have a differ-
ent prognosis. For example, H3 K27M mutant gliomas (brown) can 
have a low- or high-grade histological appearance but all have a poor 
prognosis. Conversely, BRAF-mutant gliomas cover a wide spectrum 
prognoses ranging from benign to highly malignant tumours. The dia-
gram is for illustrative purposes and does not reflect frequencies of 
any of these entities
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useful is the additional testing for mutations in the promoter 
region of telomerase reverse transcriptase (TERT), which 
leads to an upregulation of the telomerase complex activity, 
increasing tumour cell survival. Two hotspots in the TERT 
promoter (C228T or C250T) are strongly associated with 
oligodendrogliomas. Whilst TERT promoter mutations are 
also seen in a proportion of IDH-wildtype glioblastomas and 
other tumours, they are generally not seen in IDH-mutant 
astrocytomas [24]. IDH-mutant glioblastomas almost never 
show EGFR amplification, unlike their IDH-wildtype coun-
terparts (see below) [41]. Of note, IDH mutations also are 
mutually exclusive with mutations in the BRAF gene (see 
below and Fig. 2).
Clinical relevance
The prognosis is currently determined more by the patient’s 
age, performance status and the molecular genetic profile 
of IDH-mutant tumours, than by standard treatment options 
such as surgery, radiotherapy and chemotherapy [57]. The 
combination of IDH mutation and 1p/19q codeletion pre-
dicts a favourable response to upfront combined radio-
chemotherapy. The importance of a 1p/19q codeletion, in 
particular, in anaplastic oligodendrogliomas has been dem-
onstrated in several prospective phase 3 trials [56]. While 
IDH-mutant astrocytomas have a poorer prognosis than 
IDH-mutant, 1p/19q codeleted oligodendrogliomas, IDH-
mutant glioblastomas have a considerably better prognosis 
than IDH-wildtype glioblastomas [59]. Importantly, there 
appears to be little difference in overall survival between 
IDH-mutant WHO grade II astrocytomas and WHO grade 
III IDH-mutant anaplastic astrocytomas, in this instance 
challenging the current histological approach in assigning 
a malignancy grade to tumours [40]. A targeted therapy in 
the form of a “vaccine” has been developed against IDH-
mutant tumour cells and is currently being rolled out in a 
clinical trial [48]. The production of a specific oncometabo-
lite by IDH-mutant tumours has also led to studies measur-
ing 2-hydroxyglutarate in body fluids, such as plasma and 
urine [14], and by imaging techniques [8] to assess disease 
progression and/or response to therapy.
IDH‑wildtype gliomas: glioblastomas and their 
precursors
Genetics and pathology
Glioblastoma is the most common primary malignant brain 
tumour in adults. Glioblastoma shows a variable, but usu-
ally characteristic histopathological appearance and poses no 
diagnostic challenge in most cases. The morphological diag-
nostic features include tumour necrosis and/or microvascular 
proliferation (vessels with multilayered abnormal endothe-
lium) in a diffusely infiltrating, mitotically active astrocytic 
tumour. A challenge to diagnose glioblastoma histologically 
arises from small biopsies, which may contain only the infil-
tration zone of the tumour. It is increasingly important in 
clinical practice to recognise diffusely infiltrating gliomas, 
which do not show high-grade features by imaging or histol-
ogy, yet represent early forms of IDH-wildtype glioblastoma 
[39] (Fig. 2). Prior to the discovery of IDH mutations as 
biomarkers of diffuse astrocytomas, such “early” glioblas-
tomas were morphologically indistinguishable from other 
forms of astrocytomas but showed a rapid progression, 
posing a significant challenge to the WHO classification 
system. Currently, no specific mutation has been identified 
in IDH-wildtype glioblastomas that could serve as a useful 
biomarker, in the same way that IDH mutations do for oli-
godendrogliomas and astrocytomas. Instead, an increasing 
number of genetic and epigenetic alterations are discovered 
in IDH-wildtype glioblastomas, indicating that the nosologi-
cal entity of an IDH-wildtype glioblastoma encompasses 
tumours with multiple distinct molecular signatures. The 
molecular alterations in IDH-wildtype glioblastomas include 
mutations in the TERT promoter [24], chromosome 10q loss, 
7p gain or EGFR amplification, (some with an additional 
EGFR vIII mutation), ID2, MYCN and PDGFRA amplifica-
tions and CDKN2A/B deletions [45]. Molecular testing for 
these alterations can be helpful in identifying glioblastomas 
even in small samples, which do not demonstrate histologi-
cal diagnostic criteria for glioblastoma (Fig. 2). It is now 
well established that the p53 gene, one of the first genes 
found to be frequently altered in gliomas, can be mutant in 
both IDH-wildtype and IDH-mutant glioblastomas [25], and 
therefore the detection of p53 mutations is diagnostically 
and prognostically not relevant [2]. A small proportion of 
IDH-wildtype glioblastomas harbour a BRAF V600E point 
mutation (see below) or FGFR–TACC fusions [13].
Clinical relevance
The molecular alterations mentioned above can under cer-
tain circumstances be diagnostically useful, and thus may be 
important for adequate treatment planning. However, none 
of these tests have any proven prognostic or predictive sig-
nificance on their own. The only known biomarker indicat-
ing a benefit from treatment with a specific alkylating agent 
(temozolomide) is the methylation status of the MGMT pro-
moter. MGMT is a DNA repair protein which repairs chem-
otherapy-induced alkylation at the O6 position of guanine, 
thus counteracting the effects of alkylating chemotherapy. 
Methylation of the MGMT promoter is thought to silence 
gene expression and therefore reduce the repair activity of 
the protein. MGMT promoter methylation is associated with 
prolonged progression free and overall survival in patients 
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with glioblastoma, who are treated with temozolomide [51, 
56]. It must be noted that MGMT promoter methylation 
can occur in many other cancers and therefore cannot be 
used as a diagnostic marker. There are a number of ongoing 
clinical trials and emerging trials for both newly diagnosed 
and recurrent glioblastomas, using inhibitory drugs target-
ing specific cellular pathways or immunotherapy-based 
approaches with monoclonal antibodies or dendritic cell-
derived vaccines. However, the existence of several molecu-
larly and prognostically distinct subtypes of IDH-wildtype 
glioblastomas, and their highly infiltrative nature may con-




Somatic mutations in the BRAF gene were initially dis-
covered in melanomas and in a wide range of other can-
cers including colorectal and ovarian tumours as early as 
2002 [12]. A decade later, mutations in the BRAF gene, the 
V600E point mutation in particular, have been demonstrated 
in a range of low-grade IDH-wildtype glial and glioneuronal 
tumours [47], and also are increasingly recognised in malig-
nant variants [47, 53]. Mutations in the BRAF gene activate 
the MAP kinase pathway cascade, stimulating cell growth. 
Tumours in which this point mutation is most commonly 
found are pleomorphic xanthoastrocytoma (PXA, 60%), 
ganglioglioma and gangliocytoma (30%), subependymal 
giant cell astrocytoma (SEGA, 40%), desmoplastic infan-
tile glioma (10%) and pilocytic astrocytoma (5% infratento-
rial and 20% supratentorial) [3, 10]. Unlike the well-defined 
molecular classes of IDH-mutant tumours, the V600E point 
mutation in the BRAF gene occurs only in a subset of these 
nosological tumour entities. In other words, while the pres-
ence of IDH mutation is required for the molecular diagnosis 
of an astrocytoma or oligodendroglioma, in tumours such as 
ganglioglioma, pleomorphic xanthoastrocytoma or pilocytic 
astrocytoma the BRAF V600E mutation is not always pre-
sent. The BRAF V600E mutation has also been documented 
in a morphological variant of glioblastoma (epithelioid glio-
blastoma). It is being debated if epithelioid glioblastoma 
represents the most malignant form of PXA [53].
Currently, the detection of the BRAF V600E mutation is 
diagnostically useful for confirmation of a neoplastic pro-
cess, but it does not identify a specific nosological entity. 
With personalised, targeted therapy in mind, in the future 
it may be more relevant to test for this mutation rather than 
providing a detailed histological characterisation of these 
brain tumours.
Apart from a single substitution V600E mutation, other 
mutations in the BRAF gene, which can occur in IDH-
wildtype gliomas and glioneuronal tumours, include rear-
rangements, duplications and fusions with other genes and 
their detection may be diagnostically helpful. KIAA1549-
BRAF fusions are particularly frequently seen in pilocytic 
astrocytomas, a low grade, predominantly paediatric tumour 
arising most commonly in the posterior fossa. This fusion 
mutation is most common (approximately 85%) in posterior 
fossa pilocytic astrocytomas, and less frequently (50–60%) 
in hemispheric and diencephalic locations [10]. Those pilo-
cytic astrocytomas which do not harbour KIAA1549–BRAF 
fusion mutations, have been found to have mutations in 
genes encoding constituents of the MAP kinase pathway, 
including FGFR1 and NTRK gene family, NF1, PTPN11, 
KRAS and RAF1 [10, 21, 60].
Clinical relevance
Inhibition of the activating effects caused by the BRAF 
V600E mutation was the rationale for developing inhibitor 
drugs interrupting the BRAF/MEK component of the MAP 
kinase pathway. Target-specific drugs (e.g. Vemurafenib, 
Dabrafenib) were developed and initially approved for the 
treatment of BRAF V600E mutant melanomas, and have 
since been trialled first in malignant, and more recently in 
low-grade BRAF V600E mutant brain tumours [1, 35]. The 
development of drug resistance has led to the generation of 
MEK inhibiting drugs (e.g. Trametinib, Cobimetinib) which 
seem to be effective in combination with BRAF inhibitors 
[16, 18]. BRAF fusions have no known prognostic value, 
however, tumours bearing these mutations may in the future 
benefit from MAP kinase pathway inhibitors [43].
Histone‑mutant gliomas
Genetics and pathology
Mutations in the histone genes have recently been demon-
strated in several malignant tumours, including high-grade 
gliomas. Several histone gene families exist, and the most 
commonly affected histone genes in brain tumours encode 
histone variant H3.3 (H3F3A, H3F3B), and less commonly 
histone variant H3.1 (HIST1H3B, HIST1H3C) [22]. The 
identified missense mutations affect three specific amino 
acids in the N-terminal tail of histone H3 (i.e. K27M, G34R 
and G34V). These mutations are highly specific, and are 
considered as “driver” mutations, i.e. tumour-initiating [49]. 
The histone H3.3 K27M mutation almost exclusively occurs 
in CNS tumours of the midline (thalamus, basal ganglia, 
brain stem and spinal cord) mostly in children, but as the 
mutation can be easily detected by immunohistochemistry 
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with a histone H3.3 K27M mutation-specific antibody, it 
is increasingly frequently identified also in adults [6]. The 
H3 K27M mutant diffuse midline gliomas of the brain stem 
are also known as diffuse intrinsic pontine gliomas (DIPG). 
H3 K27M mutant gliomas correspond to WHO grade IV 
(i.e. the most malignant grade) irrespective of their histo-
logical appearance. Therefore, these tumours form the first 
entity in the WHO classification in which the molecular 
signature, rather than the morphology, defines the grade of 
malignancy. Instead tumours outside the midline, i.e. in the 
cerebral hemispheric regions, more commonly carry the his-
tone H3.3 G34R or rarely G34V mutations. The majority 
of these mutations are found in the H3F3A gene. A propor-
tion of histone-mutant tumours also harbour mutations in 
the ATRX gene. These often result in the loss of nuclear 
protein expression in tumour cells, which can be detected 
by immunohistochemistry and thus facilitate a more rapid 
histological diagnosis (Fig. 2).
Clinical relevance
For paediatric patients with diffuse intrinsic pontine gliomas 
(DIPG), the largest group of histone-mutant tumours, treat-
ment options are very limited with no effective conventional 
chemotherapeutic agents, and radiation therapy being the 
standard of care, with a poor survival rate of less than 10% 
2 years after diagnosis [26]. Although as of now, there is 
no specific treatment available for histone-mutant gliomas, 
the discovery of mutations in histone genes and ongoing 
further research into the underlying mechanisms has laid 
the foundation for the development of targeted therapies 
with the aim to inhibit histone methylase and demethylase 
(reviewed in [26]). H3.3 K27M mutations lead to a global 
reduction of trimethylated H3K27 (H3K27me3). The level 
of trimethylation at this residue is regulated by the methyl-
ating enzyme EZH2 and the de-methylating JMJD3. High 
EZH2 levels correlate with poor overall survival, suggesting 
it as a potential target, and experimental preclinical studies 
are promising [29]. Another strategy focuses on the inhibi-
tion of the demethylase JMJD3; such a treatment has been 
successful in preclinical studies (reviewed in [50]).
Other low‑grade glial and glioneuronal tumours
Genetics and pathology
This paragraph summarises a number of rare, histologically 
diverse tumours, comprising dysembryoplastic neuroepithe-
lial tumour (DNET), the above-mentioned ganglioglioma 
with its histological and grading variants (gangliocytoma, 
a predominantly neuronal variant, and anaplastic gangli-
oglioma, a malignant variant). Other rare entities in this 
group are desmoplastic infantile astrocytoma (DIA) and 
ganglioglioma (DIG), papillary glioneuronal tumour, rosette 
forming glioneuronal tumour (RGNT), diffuse leptomenin-
geal glioneuronal tumour (also described as disseminated 
oligodendroglioma-like leptomeningeal neoplasm [42]), 
central neurocytoma and cerebellar liponeurocytoma. Apart 
from the anaplastic form of the ganglioglioma these lesions 
are well-differentiated, slow-growing neoplasms, which have 
distinct histologies, and varied genetic profiles. The BRAF 
V600E mutations occur in a proportion of gangliogliomas 
(see above) and rarely in DIA/DIG. Papillary glioneuronal 
tumours are rare, clinically benign and are characterised 
by a very specific chromosomal translocation resulting in 
a fusion oncogene SLC44A1–PRKCA [4]. RGNT occurs in 
the fourth and occasionally in the third ventricle and else-
where periventricularly. They are rare, have a distinctive 
rosetting histological pattern and harbour mutations in the 
PIK3CA and FGFR1 genes [17], but they currently have 
little diagnostic value as the histology is characteristic and 
unique in most instances. The rare diffuse leptomeningeal 
glioneuronal tumour has entered the 2016 update of the 
WHO classification as a new entity. Although it often shows 
histological similarities to oligodendroglioma, and harbours 
a solitary 1p or combined 1p/19q deletion, importantly it is 
not IDH mutant. KIAA1549–BRAF fusions can be present 
either alone or in conjunction with the 1p or 1p/19q dele-
tions in diffuse leptomeningeal glioneuronal tumours [42]. 
An important differential diagnosis to this tumour is the 
pilocytic astrocytoma, which can have similar histological 
features (for example, clear cell morphology and leptome-
ningeal spread) and often harbours the KIAA1549–BRAF 
fusion. The central neurocytoma has a characteristic histol-
ogy and apart from WNT pathway activation and MYCN 
amplification in some tumours, no characteristic mutations 
have been identified. Central neurocytoma can resemble, 
histologically, an oligodendroglioma, but can be molecu-
larly easily discriminated as they have no IDH mutations 
or 1p/19q codeletion. A group of histologically relatively 
indistinct low-grade astrocytomas in children and young 
adults have emerged over the last years. These tumours do 
not harbour mutations in the IDH, BRAF or histone genes, 
but instead are characterised by MYBL gene rearrangements 
[37, 38, 60], which are thought to be driver mutations.
Clinical relevance
Most of the low-grade glial and glioneuronal tumours are 
benign have distinct histologies and the molecular markers 
identified in research studies are therefore of limited diag-
nostic value. Given their rarity and relatively indolent clini-
cal behaviour, it is also unlikely that these tumours will be 
on the priority list in the near future for the development of 
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Ependymomas (and their variants subependymoma and 
myxopapillary ependymoma) are glial neoplasms predomi-
nantly arising within, or in the vicinity of, the ventricles and 
the spinal cord. The molecular classification of ependymo-
mas has proven more meaningful for prognostication than 
the histological grading [31, 58], and although the nosologi-
cal entity of anaplastic ependymoma is still recognised in the 
2016 update of the WHO classification, it is clearly acknowl-
edged that there is no association between histological grade 
and biological behaviour or survival. Over the last decade, 
distinct molecular subgroups of ependymomas have been 
demonstrated with various genetic techniques. Recently, a 
uniform molecular classification scheme has been proposed, 
based on DNA methylation profiling, resulting in nine dis-
tinct molecular subgroups (Fig. 3): three molecular groups 
are allocated to each, supratentorial, posterior fossa and spi-
nal locations. In the supratentorial location, ependymomas 
with the presence of a fusion gene between C11ORF95 and 
RELA (ST-EPN-RELA) have a poor prognosis, and in the 
posterior fossa location the ependymoma group PF-EPN-A 
is characterised by a poor prognosis. All other ependymo-
mas [the two remaining supratentorial groups ST-EPN-YAP 
(YAP fusion) and ST-EPN-SE (subependymoma) and the 
two remaining infratentorial groups PF-EPN-B, PF-EPN-SE 
(subependymoma)] show a comparatively good prognosis 
[31]. As all spinal ependymomas have a good prognosis 
(when completely surgically resected), a molecular char-
acterisation is not essential in routine clinical pathological 
practice. Surrogate markers have recently been identified for 
some of these subgroups and can be easily implemented into 
routine diagnostic practice. Immunohistochemical detection 
of the global reduction of H3K27me3 is highly sensitive and 
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Fig. 3  Diagrammatic summary of the most recent molecular sub-
grouping of ependymomas based on DNA methylation patterns [30, 
31]. These molecular subgroups are genetically, epigenetically, tran-
scriptionally, demographically and clinically distinct. Three topo-
graphically distinct overarching groups are identified, supratentorial 
(ST), posterior fossa (PF) and spinal (SP). Within each group there 
are three molecularly distinct molecular subgroups. Two of these nine 
groups are characterised by poor 5 year survival. The molecular pro-
file column includes the immunohistochemically detectable surrogate 
markers of the PF-EPN-A and ST-EPN-RELA. All spinal tumours 
show favourable outcome when surgically completely removed
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specific for PF-EPN-A and robustly discriminates them from 
PF-EPN-B, thus aiding prognostication [32]. The ST-EPN-
RELA subgroup can be identified by immunostaining for the 
surrogate markers L1 cell adhesion molecule (L1CAM) or 
anti-NFkB (p65, RelA) [15], the latter based on the discov-
ery that C11orf95–RELA fusions drive oncogenic NF-kB 
signalling in ependymoma [33].
Clinical relevance
It is recommended that outside clinical trials, the WHO 
grading of ependymal tumours should not be used for the 
treatment decision [30]. Instead, the demonstration of nine 
clinically, demographically and molecularly distinct epend-
ymoma entities offers new opportunities for (molecular) 
evidence-based treatments. A consensus publication [30] 
emphasises the controversy of the traditional histologi-
cal grading system, and highlights the importance of the 
recognition of the molecular subgroups and mandates the 
use of the molecular classification of ependymomas for the 
enrolment in prospective clinical trials. However, as the rec-
ognition of the molecularly distinct subgroups is a recent 
development, no validated clinical trial data are available 
yet. This provides opportunities for the development of pre-
clinical model systems and inclusion of advanced, genome 
wide molecular tests, such as methylation arrays and subse-
quent algorithmic classification into the routine diagnostics 
of supratentorial and infratentorial ependymomas.
Conclusion and outlook
Many of the tumour entities described in this review are 
now defined by the presence of a mutation that serves as a 
biomarker, and there is now a consensus that certain brain 
tumour types should be diagnosed according to distinct 
biomarker profiles rather than histological features alone. 
It is striking, that the histological grade in some entities has 
become subordinate to the molecular profile, e.g. in epend-
ymomas [31] and possibly also in IDH-mutant astrocytomas 
[40]. Continuous advances in next generation sequencing 
and methylation arrays will increasingly aid the diagnosis of 
some brain tumour entities [52] and help the prognostication 
of others [46]. A molecular classifying algorithm based on 
DNA methylation profile has been developed for most types 
of brain tumours, helping pathologists in establishing the 
diagnosis of histologically unusual tumours and to determine 
the molecular subclasses for example of medulloblastomas 
or ependymomas (http://www.molecularneuropathology.
org). In those entities, e.g. Histone H3-, or IDH-wildtype 
glioblastomas, where no driver mutations are found, identi-
fication of molecular heterogeneity and characterisation of 
molecular subgroups in histologically similar tumours will 
help in the design of novel, more effective targeted thera-
pies. The main clinical relevance of identifying specific (epi) 
genetic alterations in each tumour is in their potential to 
serve as target for inhibitor drugs, or for the development 
of therapies, such as immunotherapy with vaccines aiming 
at the destruction of cells expressing a mutant protein [48].
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